Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Investor Presentation (June 2024)
29 slides from Health X Platform's investor presentation, Jun 10, 2024
Slide 1: Regulation 30 intimation letter to stock exchanges
SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002 Date: 10-06-2024 To To Th
Slide 2: Investor Presentation June 2024
“Digital Platform of Pharma Supply Chain and Diagnostic providing access of quality healthcare for all” Investor Presentation June 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Quote from Hon'ble Prime Minister of India
In this digital age, we have an opportunity to transform the lives of people in ways that were hard to imagine in the past. I see technology as a means of empowerment and as a tool that bridges the distance between hope and opportunity in this digital age. Shri Narendra Modi Hon’ble Prime Minister o
Slide 5: Leading Player in Indian Pharmaceutical & ePharmacy Distribution
Leading Player in Indian Pharmaceutical & ePharmacy Distribution B2C Platform • Strategic Partnership with Flipkart Pharmacy and Wellness Significant Play B2B Platform • eB2B platform distributing pharma and other in healthcare products to Pharmacies & other Pharmaceutical & other Retailers Healthca
Slide 6: Operating in High Growth Sectors – US$ 37 bn Addressable Market
Operating in High Growth Sectors – US$ 37 bn Addressable Market Growing at ~12% CAGR Indian Pharma Market ePharma Diagnostic (IPM) • Market size US$345 mn in • Market size US$24 bn 2 • Market size estimated US$ 13 2021 1 bn in 2023 3 • To grow at CAGR of 12% • To grow at CAGR of 14% • To grow at CAG
Slide 7: Q4 FY24 Key Financial Highlights – Healthcare Network
Q4 FY24 Key Financial Highlights – Healthcare Network Revenue ₹ cr ↓ 2.9 % YOY Gross Margin ₹ cr ↓ 70 bps YOY 40.0 10.6% 12.0% 366.8 9.9% 355.4 35.0 35.1 330.1 35.0 8.5% 311.5 302.5 10.0% 31.1 30.0 7.6% 6.9% 8.0% 25.0 23.8 20.8 20.0 6.0% 15.0 4.0% 10.0 2.0% 5.0 0.0 0.0% Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q
Slide 8: FY24 Key Financial Highlights – Healthcare Network
FY24 Key Financial Highlights – Healthcare Network Revenue ₹ cr ↑ 30.7% YOY Gross Margin ₹ cr ↑ 160 bps YOY 140 10.00% 1,354.8 122.0 9.0% 9.00% 120 7.4% 8.00% 6.5% 1,036.9 100 7.00% 76.5 6.00% 80 5.00% 623.0 60 4.00% 40.6 40 3.00% 2.00% 20 1.00% 0 0.00% FY22 FY23 FY24 FY22 FY23 FY24 Chasing Growth w
Slide 9: Most Capital Efficient Player in Industry
Most Capital Efficient Player in Industry Working Capital (No of Days) Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Inventory 52 43 42 37 35 Working Capital Days ↓ 24% YOY Receivable 10 12 10 12 13 50 14% 46 45 44 Payable 16 12 17 17 13 12% 40 13% 12% 36 35 35 10% Working Capital (No of Days) 46 44 36 31 35 3
Slide 10: Pillars of Growth
Pillars of Growth Growing Platform in ePharmacy Consolidation in Indian Pharma Distribution Diagnostic Services To launch eHealth app “Genu Health” 9
Slide 11: Growing Platform in ePharmacy
Growing Platform in ePharmacy Strategic partnership built on strong capabilities 75.10% 24.90% stake stake • Large consumer base • Most efficient supply chain & fulfilment capabilities • Established consumer tech capabilities • Direct procurement relationship with 250+ Pharma Companies • Huge brand
Slide 12: Structural Shift – Consolidation on way in Indian Pharma Distribution
Structural Shift – Consolidation on way in Indian Pharma Distribution Pharmaceutical wholesaling/distribution is highly consolidated industry in most of the developed countries (period last 2 to 3 decades). India to witness similar consolidation in Pharmaceutical distribution with fewer having major
Slide 13: Pharma eDistribution – Digital Supply Chain of Pharmaceuticals
Pharma eDistribution – Digital Supply Chain of Pharmaceuticals & Other Healthcare Products • Digital Supply Chain poised to transform the Indian Pharma distribution benefiting everyone with Pharma Companies major beneficiary • Improved Business Forecasting Digital supply chain can lower • Inventory
Slide 14: Benefitting Pharma & FMCG Cos.
Benefitting Pharma & FMCG Cos. • End to End tracking of Inventory up to Retailers with real time data • Better managed inventory leading to reduced return of expired stocks • Better production and distribution planning • New drugs can be introduced faster • Huge scope for Pharma Companies for their
Slide 15: Benefitting Retailers - Transforming Economics & Lives of Retailers
Benefitting Retailers - Transforming Economics & Lives of Retailers Traditional Distributors Benefits to Retailers • Full visibility of Inventory online • Reduction of Inventory Lead Time • Sourcing from Multiple Distributors • 100% fulfilment • Lower Working Capital requirement • Fulfilment gaps •
Slide 16: Empowering Retailers – One Stop eProcurement Solution
Empowering Retailers – One Stop eProcurement Solution Widest Availability and 100% Genuine High Margins with Fulfilment of Products Products Transparent Pricing (65000+ Products) Automated Procurement Timely Delivery Clear Return Policy 15
Slide 17: Snapshot
Snapshot Genu Path Labs, an NABL ACCREDITED LAB, where everything revolves around Meticulous Assay of Quality Evidence. Highly experienced Clinical Team, Advanced High End Lab Equipment, Stringent Quality Norms – EQAS, ILC, Strong Process Control (QuaGenLR) – we employ all of these at Genu 26+ Sampl
Slide 18: GENU Health app - Under making of Powerful Health Solutions
GENU Health app - Under making of Powerful Health Solutions • Direct service to the consumers from Genu Path Labs as D2C Brand offering diagnostic services with seamless integration of technology • Centred around preventive care, diagnostic services, management of surgery and hospital care, health/d
Slide 19: Sastasundar Group – Value Proposition
Sastasundar Group – Value Proposition • Best in class Customer Experience driven by Value Pricing, Quality and Tech • Clear visibility of high growth with EBITDA + model • Capital efficient with high ROCE • Strong MOAT ⁻ Established Business Technology with highly efficient supply chain ⁻ Managing 1
Slide 20: Experienced Board of Directors
Experienced Board of Directors FCA, FCS and FCM by education and has an experience of FCA by education and is a seasoned entrepreneur with more than 23 years working as an entrepreneur and a experience in scaling businesses from scratch. social worker. Areas of work include digital platform of
Slide 21: Experienced Management Team – Healthcare Network
Experienced Management Team – Healthcare Network Sachin Mittal COO Vinay Khaitan CTO Dinkar Bagaria CFO Past Experience - Amazon, Novartis Past Experience - Flipkart Group, Past Experience – TIL Ltd, SPML Infra, SastaSundar Group, GEO India McNally Bharat, Balasore Alloys 10+ Years of Experience 25+
Slide 22: Q4 FY24 Consolidated Profit & Loss Statement
Q4 FY24 Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q4 FY24 Q4 FY23 Y-o-Y Q3 FY24 Q-o-Q FY 23-24 FY 22-23 Y-o-Y Revenue from Operations 302.5 311.5 (2.9%) 366.8 (17.5%) 1,354.8 1,036.9 30.7% Cost of Materials Consumed 281.7 287.7 335.7 1,232.8 960.4 Gross Profit 20.8 23.8 (12.6%) 31.1
Slide 23: Breakup of Revenue (Vertical)
Breakup of Revenue (Vertical) Particulars (Rs. Crs) Q4 FY24 Q4 FY23 Q3 FY24 FY24 FY23 Supply chain HealthBuddy 129.6 251.5 236.7 863.2 822.1 Other Retailers 172.1 59.3 129.5 488.6 211.5 Diagnostic 0.8 0.7 0.6 3.0 3.3 Healthcare Network 302.5 311.5 366.8 1,354.8 1,036.9 Financial Services 22.6 10.4 2
Slide 24: Annual Financial Highlights
Annual Financial Highlights Rs. In Crs Revenue from Operations Gross Profit Q4 4.5% 8.8% 6.5% 7.4% 9.0% Q3 +252.0% Q2 +617.6% 1,355 Q1 122 303 1,037 21 312 367 77 31 622 24 540 280 157 355 48 35 385 132 41 141 11 22 116 134 254 12 10 155 17 8 103 140 13 10 19 35 330 92 134 169 191 4 55 12 13 12 74 3
Slide 25: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Revenue from Operations 1,354.8 1,036.9 623.0 540.0 384.0 Cost of Materials Consumed 1,232.8 960.4 582.5 492.5 366.9 Gross Profit 122.0 76.5 40.5 47.5 17.1 GP % 9.0% 7.4% 6.5% 8.8% 4.5% Employee
Slide 26: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Equity & Liabilities (Rs. Crs) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Assets (Rs. Crs) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 71.6 68.1 57.2 57.3 60.2 Capital Work-in-Progress 0.4 1.0 0.4 0.1 0.
Slide 27: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Cash Flow from Operating Activities Profit before Tax (30.5) (122.3) 1,109.5 (16.4) (57.6) Adjustment for Non-Operating Items 25.8 84.0 (1,151.0) (3.2) 4.8 Operating Profit before Working Capital Cha
Slide 28: 'Being Genuine' is Our Core Value 'Being Child' is Our Culture
‘Being Genuine’ is Our Core Value ‘Being Child’ is Our Culture 27
Slide 29: Thank You
Company: Thank You SastaSundar Ventures Limited CIN: L65993WB1989PLC047002 Mr. Pratap Singh – Company Secretary Email Id : investors@sastasundar.com www.sastasundarventures.com Investor Relations Partner: Orient Capital (a division of Link Group) Ronak Jain Irfan Raeen Ronak.jain@linkintime.co.in Ir
Sastasundar Ventures — Investor Presentation (June 2024) on 6ix